Donoghue Forlines’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-42,687
| Closed | -$1.21M | – | 247 |
|
|
2024
Q3 | $1.21M | Buy |
42,687
+20,211
| +90% | +$572K | 0.34% | 105 |
|
|
2024
Q2 | $593K | Buy |
22,476
+1,719
| +8% | +$45.3K | 0.17% | 139 |
|
|
2024
Q1 | $630K | Buy |
+20,757
| New | +$630K | 0.18% | 143 |
|
|
2023
Q3 | – | Sell |
-11,712
| Closed | -$360K | – | 279 |
|
|
2023
Q2 | $360K | Sell |
11,712
-6,723
| -36% | -$207K | 0.11% | 200 |
|
|
2023
Q1 | $664K | Buy |
18,435
+12,916
| +234% | +$465K | 0.24% | 114 |
|
|
2022
Q4 | $218K | Sell |
5,519
-1,037
| -16% | -$41K | 0.08% | 211 |
|
|
2022
Q3 | $263K | Sell |
6,556
-9,359
| -59% | -$375K | 0.09% | 187 |
|
|
2022
Q2 | $669K | Buy |
15,915
+3,133
| +25% | +$132K | 0.17% | 144 |
|
|
2022
Q1 | $498K | Buy |
+12,782
| New | +$498K | 0.11% | 250 |
|